Treatment of refractory rheumatoid arthritis with a tumor necrosis factor α receptor fusion protein (TNFR55-IgG1) results from double-blind placebo-controlled 3 month trials;Therapie der refraktaren chronischen polyarthritis mit tumornekrosefaktor α rezeptor-fusionsproteinen (TNFR55-IgG1) - Ergebnisse aus doppelblinden placebokontrollierten studien uber 3 monate

Zeitschrift fur Rheumatologie

Volumn 57, Issue 5, 1998, Pages 302-306

  Van De Putte, L B A ^a   Sander, O ^b   Rau, R ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Evangelisches Fach krankenhaus Ratingen   (Germany)

Author keywords

NFR IgG; Receptor fusion protein; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; PLACEBO; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; LEUKOCYTE ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INFUSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POLYARTHRITIS; REFRACTORY PERIOD; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; AGED; ARTICLE; CHEMISTRY; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0031593799     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050116     Document Type: Conference Paper

References (8)

1. Elliot MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
2. Hasler F, van de Putte L, Baudin M et al (1996) Chronic TNF neutralisation (up to 1 year) by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis: results of an open-label extension of a double-blind single dose phase I study. Arthritis Rheum 39:S243 (abstract)
3. Sander O, Rau R, van Riel P et al (1996) Neutralisation of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 39:S242 (abstract)
4. Furst D, Weisman M, Paulus H et al (1996) Neutralisation of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a US phase II trial. Arthritis Rheum 39:S243 (abstract)
5. Rau R, Sander O, Schattenkirchner M et al (1996) Monthly vs. bimonthly dosing of Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a double-blind controlled phase II trial. Arthritis Rheum 39:S243 (abstract)
6. Kneer J, Dumont E, Birnböck H et al (1996) A new TNF neutralizing agent - Lenercept (TNFR55-IgG1, Ro 45-2081): Pharmacokinetic/-dynamic data over a 100-fold dose-range in healthy volunteers and rheumatoid arthritis patients. Rheumatology in Europe 25:S52 (abstract)
7. Rau R, Sander O, Furst D et al (1998) Intravenous monthly human recombinant TNF receptor P55-FcIgG1 fusion protein, Ro 45-2081: double-blind, placebo-controlled dose-finding studies in long-standing, active rheumatoid arthritis. Ann Rheum Dis, submitted
8. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147